YYZ Pharmatech Inc. (“YYZ”) is a deep tech company committed to advancing transformative medicines for patients by revealing first-in-class and novel cell-surface co-receptor drug targets that others miss. YYZ's platform characterizes cell-surface receptor complexes with unprecedented sensitivity to derive the most compelling drug targets for new therapies. YYZ is a member of JLABS and a spinout from Professor John G. Marshall's laboratory at Toronto Metropolitan University. Our pioneering science is built on a foundation of +150 publications and extensive collaboration with leading international institutions.